Open Access

Erratum to: Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit

  • Meng-Hsing Ho1,
  • Teng-Wei Chen1,
  • Kuang-Wen Ou2,
  • Jyh-Cherng Yu1 and
  • Chung-Bao Hsieh1Email author
World Journal of Surgical Oncology201715:91

DOI: 10.1186/s12957-017-1156-x

Received: 20 April 2017

Accepted: 20 April 2017

Published: 28 April 2017

The original article was published in World Journal of Surgical Oncology 2017 15:83

Erratum

Upon publication of the original article [1], an error was discovered in Table 1 (the tumor location of the 9th patient). This mistake was owing to typing error. This has now been corrected in this erratum and the original manuscript has been updated. We apologise for any inconvenience caused by this error.
Table 1

Demographic data of patients undergoing curative surgery

Patient

Sex

Age (y)

Diagnosis

Child class (score)

Tumor marker

Location of hepatic tumor

Thrombi location

Pre-operative therapy

1

F

68

Leiomyosarcoma of IVC with liver invasion

Non-cirrhosis

N/A

Seg 1,2,3

Reaching the hepatocaval junction

N

2

F

46

HBV-related HCC

A (5)

AFP: 5000 ng/dL

Seg 7,8

Near the hepatocaval junction

N

3

M

57

HBV-related HCC

A (6)

AFP: 4000 ng/dL

seg 5,6,7,8

Reaching the hepatocaval junction

N

4

F

38

Adrenocortical carcinoma with liver

Non-cirrhosis

N/A

seg 4,5,6,7,8

Reaching the hepatocaval junction

N

5

M

72

HBV-related HCC

A (5)

AFP: >40 000 ng/dL

seg 4,5,6,7,8

Near the hepatocaval junction

N

6

M

46

HBV-related HCC

A (5)

AFP: >40 000 ng/dL

seg 7

Near the hepatocaval junction

N

7

M

29

HBV-related HCC

A (5)

AFP: >40 000 ng/dL

seg 5,6,7,8

Near the hepatocaval junction

N

8

M

46

HBV-related HCC

A (5)

AFP: >40 000 ng/dL

seg 6,7,8

Reaching the hepatocaval junction

TACE + Sorafenib

9

M

86

Non-HBV or –HCV-related HCC, sacromatoid type

A (5)

AFP: 2.29 ng/dL

seg 4

Reaching the hepatocaval junction

TACE + Sorafenib

10

M

40

HBV-related HCC

A (5)

AFP: 168.5 ng/dL

seg 5,6

Reaching the hepatocaval junction

TACE + Sorafenib

Mean

 

52.8

      

SD

 

17.7

      

AFP alpha-fetoprotein, HBV hepatitis B virus, F female, HCC hepatocellular carcinoma, HCV hepatitis C virus, M male, TACE transarterial chemoembolization

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center
(2)
Divisions of Plastic Surgery and General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center

Reference

  1. Ho MH, Chen TW, Ou KW, Yu JC, Hsieh CB. Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit. World J Surg Oncol. 2017;15(1):83.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement